Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07069569 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 1 → 14 locationsv5
  2. Trial status: Active, Not Recruiting to Recruitingv4 Show 7 more changesShow less
    • Enrollment target: 127 to 200
    • Primary completion date: Jan 1, 2027 to Jul 15, 2027
    • Study completion date: May 1, 2027 to Jan 15, 2028
    • Start date: May 30, 2025 to Jun 8, 2025
    • Secondary endpoints: 14 to 15
    • Site details revised
    • Study arms: 4 to 5
  3. Secondary endpoints: details revised at 1 of 14 entriesv3
  4. Trial status: Recruiting to Active, Not Recruitingv2 Show 4 more changesShow less
    • Enrollment target: estimated 120 to confirmed 127
    • Interventions: AHB-137 (Drug), AHB-137 and Hepatitis B vaccine (Drug), AHB-137 and Peg-IFN (Drug), AHB-137 and Peg-IFN (Drug) to AHB-137 (Drug), Hepatitis B Vaccine (Drug), Peg-IFN (Drug)
    • Secondary endpoints revised (14)
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of AHB-137 injection in combination with other hepatitis B drugs in participants with HBeAg-negative CHB treated with NAs.
Trial Details
NCT Number NCT07069569
Lead Sponsor Ausper Biopharma Co., Ltd.
Conditions
(from sponsor)		 Chronic Hepatitis B
Related terms Hepatitis B, Chronic
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov